FAES FARMA – DOWN BUT NOT OUT (ADD; 14% UPSIDE)
10/06/21 -" When we last teased about Faes Farma (Add, Spain) in July 2020, the small pharma firm was under pressure due to lower demand for its anti-allergy / histamine drug, Bilastine (c.27% of sales), in the ..."
Pages
44
Language
English
Published on
10/06/21
You may also be interested by these reports :
13/05/24
Lundbeck’s 2023 profitability fell short of our expectations as, despite some yoy improvement, margins were under pressure from higher SG&A related ...
10/05/24
Novonesis reported largely in-line Q1 24 numbers. Q1 24 revenue was up 45% on a pro-forma basis, helped by strong performances in the key segments of ...
08/05/24
Sandoz is moving ahead well with two crucial aspects of its medium-term sales and profitability goals: 1/ a strong performance from Biosimilars and ...
07/05/24
Q1 sales missed the consensus estimates, although the CER growth was largely in line with the firm’s full-year outlook. Biosimilars were the main ...